Navigation Links
Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
Date:8/19/2010

ed thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV Pharma
2. Perrigo Announces FDA Approval for Over-the-Counter Cetirizine Cherry Syrup
3. Perrigo Company Confirms Patent Challenge for Clobetasol Propionate Emulsion Foam
4. Perrigo Acquires Exclusive Sales and Distribution Rights to OTC Store Brand Versions of Allegra® and Allegra D-12 From Teva
5. Perrigo Company to Present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging and Leisure Conference
6. Perrigo Company to Present at the 31st Annual Goldman Sachs Global Healthcare Conference
7. Perrigo Announces FDA Final Approval for Miconazole
8. Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
9. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
10. Perrigo Company Announces Quarterly Dividend
11. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 National Community Pharmacists Association (NCPA) ... the following statement in response to a new ... documenting that a number of generic drug costs increased ... with concerns previously expressed by NCPA and underscores the ... to essential medications. Moreover, a 2015 survey of 700 ...
(Date:5/28/2015)... , May 27, 2015 The amount ... billion in 2014 and with growth of 8% will ... categories out of pocket: directly on expenditures, co-pays as ... purchases, and on premiums.  The publisher made its finding ... in the United States . ...
(Date:5/28/2015)...  The U.S. Department of Justice (DOJ) has entered ... Medical Inc. to resolve a lawsuit that began more ... whistleblower lawsuit by two former employees of Orbit.  The ... of one of Orbit,s top executives, Jake Kilgore ... payment from Medicare for electric wheelchairs.  The lawsuit was ...
Breaking Medicine Technology:NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:5/28/2015)... 28, 2015 The Clinical Data ... that the International Organization for Standardization (ISO) now ... (BRIDG) Model version 3.2 as a published, Final ... with healthcare. This standard, which had previously passed ... was unanimously approved on 24 April for publication ...
(Date:5/28/2015)... 28, 2015 Park Cities Pet Sitter is ... Training class starting Saturday, June 6th at 10:30am. ... 5831 McCommas Blvd in Dallas, with a maximum of six ... for five weeks, with no class being held over the ... $135. , In this Intermediate-to-Advanced level class, dogs will solidify ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... opening a new location for his Shore Vascular & Vein ... treatment of the circulatory system. It is his mission ... compassion, consideration and respect. , Dr. Jeffrey Gosin ... a graduate of the University of Pennsylvania and Jefferson Medical ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... 2015 Medelis, Inc., a specialty oncology ... company in the role of president. , “ Bill Taaffe ... CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He ... our next phase of growth.” , Taaffe joined ICON’s ... nine employees to over 4,500 employees, achieving 12 consecutive years ...
Breaking Medicine News(10 mins):Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... plays a major role in kidney failure, and blocking the ... disease in diabetes, according to researchers. "We believe these ... can slow down the progression of, or even prevent the ... professor of nephrology, Penn State College of Medicine. In the ...
... News) -- Low vitamin D levels are common among spine ... says. Vitamin D helps with calcium absorption. Spine surgery ... producing new bone, explained researchers at Washington University School of ... spinal fusion surgery and found that more than half of ...
... , FRIDAY, Nov. 4 (HealthDay News) -- "Leatherhead" football ... modern helmets, a new study reports, but no one is ... researchers said their findings point to the need for improvements ... research team conducted lab tests to compare head injury risks ...
... crystallography, researchers Xiaohu Mei, PhD, and David Atkinson, PhD, from ... time obtained an "image" of the structure and the precise ... apolipoprotein A-I (apoA-I) molecule. The findings, which appear in the ... may lead to the development of new drugs to treat ...
... a new study being published early online in Annals ... College of Physicians, birth cohort screening for hepatitis C is ... strategy could identify over 800,000 currently unidentified cases, which could ... percent of the nation,s population is infected with hepatitis C ...
... A gene variation associated with an increased risk of autism ... three to four times more likely than girls to be ... genomic data from more than 3,000 children with autism and ... The results showed a link between a variation in the ...
Cached Medicine News:Health News:Research aims to prevent diabetic kidney failure 2Health News:Vitamin D Lacking in Many Spine Surgery Patients 2Health News:Newer Not Necessarily Better for Football Helmet Design 2Health News:Researchers identify structure of apolipoprotein 2Health News:Birth cohort screening for hepatitis C is cost effective, could save thousands of lives each year 2Health News:Possible Genetic Link to Autism Identified 2
An economical solution to the need to provide wrap-around protection. The one-sided velcro closure allows greater flexibility in sizing. Front protection is 0.5mm Pb and the back is 0.25mm Pb equival...
This wrap around apron features a uniquely designed orthopedic wide belt that is integrated directly on the apron....
The most comfortable and easy to use apron in the industry. This front protection apron comes with a fully adjustable snap-on 5" orthopedic belt to relieve weight off your shoulders. Velcro strap acr...
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Medicine Products: